| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Prodigiosin HCl targets multiple cellular pathways. It is a potent inhibitor of the Wnt/β-catenin signaling pathway. It significantly reduces the levels of total β-catenin, active β-catenin, and phosphorylated LRP6 and DVL2. It also strongly inhibits GSK3β Ser9 phosphorylation, indicating increased GSK3β activity. These effects lead to the suppression of Wnt target gene transcription.
|
|---|---|
| ln Vitro |
Prodigiosin treatment (25–500 nM; 24 hours) decreased the viability of breast cancer cells, with an IC50 value of 261.2 in MDA-MB-468 cells and 62.52 nM in MDA-MB-231 cells at 48 hours. nM[1]. Prodigiosin treatment (25-500 nM; 24 hours) markedly decreased the levels of total β-catenin, active β-catenin, and phosphorylated LRP6 and DVL2. In HEK293T cells, prodigiosin strongly suppresses GSK3β Ser9 phosphorylation, indicating increased GSK3β activity [1]. Breast cancer cells can undergo apoptosis and be inhibited from proliferating when exposed to prodigiosine [1]. In transfected HEK293T cells, prodigiosin treatment (25–500 nM; 24 hours) dose-dependently inhibits Wnt signaling triggered by Wnt1, Wnt3, Wnt1/LRP6, Wnt3/LRP6, and Disheveled 2 (DVL2). The Wnt3A-CM-induced transcription was dose-dependently suppressed by prodigiosin administration. When Wnt transfection or Wnt3A therapy is applied, the SuperTopFlash reporter gene's transcription is inhibited by prodigiosin [1]. Applying this substance to cultures of Batrachochytrium dendrobatidis and B. Prodigiosin and salamandrivorans both significantly restrict growth, having MIC values of 10 μM and 50 μM, respectively [2].
In vitro, Prodigiosin HCl is a potent pro-apoptotic agent. It reduces the viability of breast cancer cells, with IC50 values of 62.52 nM for MDA-MB-231 cells and 261.2 nM for MDA-MB-468 cells at 48 hours. It inhibits Wnt1, Wnt3, Wnt1/LRP6, Wnt3/LRP6, and DVL2-triggered Wnt signaling in a dose-dependent manner. It also shows antimicrobial activity, with MIC values of 10 µM against Batrachochytrium dendrobatidis and 50 µM against B. salamandrivorans. |
| ln Vivo |
Treatment with prodigiosin (5 mg/kg; intraperitoneal injection; twice weekly; for 3 weeks) effectively suppressed tumor growth. Prodigiosin therapy can lower tumor cell density and expression of the proliferation marker Ki-67 [1].
In vivo, Prodigiosin HCl has demonstrated antitumor activity. In a mouse model bearing MDA-MB-231 breast cancer xenografts, intraperitoneal administration at 5 mg/kg twice weekly for 3 weeks effectively inhibited tumor growth. This was associated with a reduction in tumor cell density and the proliferation marker Ki-67. |
| Enzyme Assay |
The biological activities of Prodigiosin HCl are assessed using a variety of in vitro assays. Its effect on cell viability is measured using standard cytotoxicity assays. Its effect on the Wnt/β-catenin pathway is assessed by measuring the levels of pathway components (e.g., β-catenin, LRP6) by Western blot and by using Wnt-responsive reporter gene assays.
|
| Cell Assay |
Cell proliferation assay[1]
Cell Types: MDA-MB-231 and MDA-MB-468 Cell Tested Concentrations: 10 nM, 25 nM, 50 nM, 100 nM, 250 nM, 500 nM, 1000 nM, 2500 nM, 5000 nM Incubation Duration: 24 hrs (hours), 48 hrs (hours). Experimental Results: Reduce the viability of breast cancer cells. The IC50 value of MDA-MB-231 cells at 48 hrs (hours) was 62.52 nM, and the IC50 value of MDA-MB-468 cells was 261.2 nM. Western Blot Analysis[1] Cell Types: HEK293T Cell Tested Concentrations: 50 nM, 100 nM, 250 nM, 500 nM Incubation Duration: 24 hrs (hours) Experimental Results: Dramatically diminished levels of phosphorylated LRP6 and DVL2, active β-catenin and total β- Catenin. The cellular activity of Prodigiosin HCl is evaluated in various cancer cell lines, such as MDA-MB-231 and MDA-MB-468 breast cancer cells, and in HEK293T cells. Cells are treated with Prodigiosin HCl, and its effects on cell viability, apoptosis, and Wnt signaling are assessed. Its antimicrobial activity is evaluated in culture against various pathogens. |
| Animal Protocol |
Animal/Disease Models: Female BALB/c nude mice were injected with MDA-MB-231 cells [1].
Doses: 5 mg/kg. Route of Administration: intraperitoneal (ip) injection; twice a week; for 3 consecutive weeks. Experimental Results: Dramatically inhibited mouse tumor growth. In animal studies, Prodigiosin HCl is typically administered via intraperitoneal (i.p.) injection. In tumor models, it is given to assess its effect on tumor growth. Dosing regimens are determined based on its pharmacokinetic properties. Tumor volume is measured, and tumors can be harvested for pharmacodynamic analysis, such as assessing proliferation and apoptosis markers. |
| ADME/Pharmacokinetics |
Prodigiosin HCl is a small molecule with a molecular weight of 359.89 and a formula of C20H26ClN3O. It is soluble in DMSO. It is typically stored as a powder at -20°C. Detailed pharmacokinetic parameters are available from preclinical studies. Its hydrochloride salt form enhances its aqueous solubility.
|
| Toxicity/Toxicokinetics |
Toxicology data for Prodigiosin HCl is limited, as it is a research compound. Its safety profile has not been established in formal toxicology studies. Its use is limited to research applications and it is not intended for human therapeutic use without further development.
|
| References |
|
| Additional Infomation |
Prodigiosin HCl (CAS: 56144-17-3) is a natural product with a diverse range of biological activities. Its potent inhibition of the Wnt/β-catenin pathway and its pro-apoptotic effects make it a valuable tool for cancer research. Its broad-spectrum antimicrobial and immunosuppressive properties also make it useful for studying bacterial physiology and immune regulation. It serves as a lead compound for the development of new therapeutic agents.
|
| Molecular Formula |
C20H26CLN3O
|
|---|---|
| Exact Mass |
359.176
|
| CAS # |
56144-17-3
|
| Related CAS # |
Prodigiosin;82-89-3
|
| PubChem CID |
136179593
|
| Appearance |
Purple to purplish red solid powder
|
| Source |
Originated from microorganisms: Serratia marcescens
|
| LogP |
5.578
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
25
|
| Complexity |
523
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC1=C(NC(=C1)/C=C\2/C(=CC(=N2)C3=CC=CN3)OC)C.Cl
|
| InChi Key |
UQRGJSTXVCWXNU-JHMJKTBASA-N
|
| InChi Code |
InChI=1S/C20H25N3O.ClH/c1-4-5-6-8-15-11-16(22-14(15)2)12-19-20(24-3)13-18(23-19)17-9-7-10-21-17;/h7,9-13,21-22H,4-6,8H2,1-3H3;1H/b19-12-;
|
| Chemical Name |
(2Z)-3-methoxy-2-[(5-methyl-4-pentyl-1H-pyrrol-2-yl)methylidene]-5-(1H-pyrrol-2-yl)pyrrole;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~10 mg/mL (~27.8 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.25 mg/mL (0.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (2.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.25 mg/mL (0.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (2.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
